Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼

Monday, May 17, 2010

Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committe

media: Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.